Clinical trials: Infliximab
Diabetic Macular Edema
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema
The purpose of this study is to determine if intravitreal infliximab is a safe and effective treatment for macular edema secondary to diabetes.
- Trial name
- NCT00959725
- Testing
- Infliximab (intravitreal, 2.0mg/0.05ml)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Rheumatoid Arthritis
The Effects of a 16-Week Individualized, Intensive Strength Training Program in Patients With Rheumatoid Arthritis
To assess the effects of a 16-week individualized, intensive strength training program in patients with rheumatoid arthritis. Primary and secondary outcomes include: strength and body composition, function, disease activity…
- Trial name
- NCT00327275
- Testing
- strength training
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Spondylitis, Ankylosing
Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)
This is a randomized, double-blind, multi-center, placebo-controlled study with two parallel treatment groups (placebo and infliximab) in subjects with ankylosing spondylitis (AS) to evaluate the efficacy of infliximab 3 mg/kg.
- Trial name
- CANDLE (NCT00202865)
- Testing
- infliximab
- Volunteers
- 76 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease
RATIONALE: Studying samples of blood from patients with cancer, hepatitis C, or Crohn disease in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer and other…
- Trial name
- NCT00897312
- Testing
- infliximab, pegylated interferon alfa, ticilimumab
- Volunteers
- 7 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Chronic Uveitis
Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis
The primary objective of this study is to examine the efficacy of infliximab for the treatment of persistent uveitis in children.
- Trial name
- NCT00589628
- Testing
- infliximab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Egla C. Rabinovich
Rheumatoid Arthritis, Spondyloarthritis
The Norwegian Drug Monitoring Study
Infliximab and other TNF-inhibitors have revolutionised the treatment of several immunological inflammatory diseases. Still, more than half of the patients either do not respond sufficiently to infliximab therapy or loose…
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Ankylosing Spondylitis, Crohn Disease
- Trial name
- NOR-DRUM (NCT03074656)
- Testing
- Therapeutic drug monitoring, Standard care
- Where
- 21 sites in Norway
- Volunteers
- 611 people
- Sponsor
- Diakonhjemmet Hospital
Inflammatory Bowel Diseases
Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)
Anti-TNF treatment (infliximab (IFX), adalimumab (ADA)) has become standard therapy for refractory pediatric and adult Crohn's disease (CD) patients, and is used for the induction (primary response) and maintenance of remission.
- Trial name
- NCT01971970
- Testing
- Infliximab, Adalimumab
- Where
- Netherlands
- Volunteers
- 45 people
- Sponsor
- Erasmus Medical Center
Spondylitis, Ankylosing
Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)
This is an open-label, controlled sub-study to the parent protocol (P04041, NCT00779935) to examine the expression profile of genes in patients in the active stage of ankylosing spondylitis (AS) compared to the healthy population…
- Trial name
- NCT00778869
- Testing
- Remicade
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Crohn Disease
Association of Breg and Treg With the Clinical Effects of Infliximab in the Treatment of Patients With Crohn's Disease
Aims: The main aim of this study is to access the predictive value of Treg and Breg for the clinical effect of Infliximab in the treatment through analyzing the relationship between Breg and Treg and the efficacy of Infliximab.
- Trial name
- NCT04272788
- Testing
- Infliximab
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Crohn Disease
Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
Crohn's disease (CD) is a life-long inflammatory bowel disease disease with an unknown pathogenesis. The ultimate goal of therapy is to modify the natural history of CD thus reducing complications.
- Trial name
- NCT03221166
- Testing
- Thalidomide, Infliximab
- Where
- 6 sites in Italy
- Volunteers
- 9 people
- Sponsor
- IRCCS Burlo Garofolo
Type 1 Diabetes
Islet Transplantation Using Campath-1H and Infliximab Induction
Islet transplantation has been investigated as a treatment for Type 1 diabetes mellitus in selected patients with inadequate glucose control despite insulin therapy.
- Trial name
- NCT00175266
- Testing
- alemtuzumab, islet transplant, infliximab
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University of Alberta
Inflammatory Bowel Disease, Crohn's Disease
The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease
In this research proposal, the investigators will focus on methods to optimize the therapeutic response to anti-TNF antibodies, by determining a correlation of 6-mp metabolite levels with IFX trough levels, anti-IFX antibody…
- Trial name
- NCT02453607
- Testing
- Infliximab, thiopurine
- Where
- Canada
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Ernest Seidman
Ulcerative Colitis
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
- Trial name
- EFFECT-1LAT (NCT07177209)
- Testing
- Non-Interventional Study
- Where
- United Kingdom
- Volunteers
- 4,000 people
- Sponsor
- Pfizer
Juvenile Idiopathic Arthritis
Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis
The purpose of this study is to analyze the frequency of the formation of antibodies against three different anti-TNF biologic agents used for the therapy of juvenile idiopathic arthritis.
- Trial name
- NCT01436019
- Where
- Slovenia
- Volunteers
- 100 people
- Sponsor
- Blood Transfusion Centre of Slovenia
Inflammatory Bowel Diseases
Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease
assessment of inflammatory bowel disease patients in activity and remission by abdominal ultrasound examine non-invasive and in physiological condition by measuring the colon wall thickness in diagnosis and follow up the patient…
- Trial name
- NCT03445624
- Testing
- Infliximab
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Arthritis, Rheumatoid, Colitis, Ulcerative
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
The purpose of this study is to learn about the safety of the safety of the study medicine called infliximab for the possible treatment of rheumatoid arthritis (RA), ulcerative colitis (UC, Crohn's disease, or psoriasis.
- Conditions
- Arthritis, Rheumatoid, Colitis, Ulcerative, Crohn Disease, Psoriasis
- Trial name
- NCT05796245
- Where
- Japan
- Volunteers
- 2,207 people
- Sponsor
- Pfizer
Inflammatory Bowel Diseases
Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.
This study aims to assess trough, TREM-1 levels and efficacy of IFX and ADA in IBD patients.
- Trial name
- NCT05291039
- Testing
- Infliximab, Adalimumab
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Rehab Werida
Pyoderma Gangrenosum, Crohn's Disease
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication.
- Conditions
- Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
- Trial name
- NCT00791557
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University Hospitals Cleveland Medical Center
Drug Monitoring, Inflammatory Bowel Diseases
Influence of HLA-DQA1*05 Genotype in Adults With Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring.
HLA-DQA1*05 variant carriers are at risk of developing antibodies against infliximab and adalimumab with reduced TNF antagonist persistence.
- Trial name
- Proa-DQ (NCT05986903)
- Testing
- Tumor necrosis factor (TNF)-alpha inhibitors
- Where
- Spain
- Volunteers
- 280 people
- Sponsor
- Hospital del Rio Hortega
Esophagitis
Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis
Eosinophilic Esophagitis (EE) is a chronic inflammatory disorder of the esophagus with a constantly increasing prevalence. It has been demonstrated that the expression of the cytokine TNF-α is up regulated in EE and that this…
- Trial name
- IEE (NCT00523354)
- Testing
- Infliximab
- Where
- Switzerland
- Sponsor
- Swiss EE Study Group